162 related articles for article (PubMed ID: 16848745)
1. Design, synthesis and in vitro evaluation of 4-androstene-3,17-dione/adenosine hybrid compounds as bisubstrate inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.
Bérubé M; Laplante Y; Poirier D
Med Chem; 2006 Jul; 2(4):329-47. PubMed ID: 16848745
[TBL] [Abstract][Full Text] [Related]
2. Chemical synthesis and in vitro biological evaluation of a phosphorylated bisubstrate inhibitor of type 3 17beta-hydroxysteroid dehydrogenase.
Bérubé M; Poirier D
J Enzyme Inhib Med Chem; 2007 Apr; 22(2):201-11. PubMed ID: 17518347
[TBL] [Abstract][Full Text] [Related]
3. Improved synthesis of EM-1745, preparation of its C17-ketone analogue and comparison of their inhibitory potency on 17beta-hydroxysteroid dehydrogenase type 1.
Bérubé M; Poirier D
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):832-43. PubMed ID: 19003559
[TBL] [Abstract][Full Text] [Related]
4. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.
Tremblay MR; Poirier D
J Steroid Biochem Mol Biol; 1998 Aug; 66(4):179-91. PubMed ID: 9744515
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.
Fournier D; Poirier D; Mazumdar M; Lin SX
Eur J Med Chem; 2008 Nov; 43(11):2298-306. PubMed ID: 18372081
[TBL] [Abstract][Full Text] [Related]
6. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
[TBL] [Abstract][Full Text] [Related]
8. Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase.
Poirier D; Boivin RP; Tremblay MR; Bérubé M; Qiu W; Lin SX
J Med Chem; 2005 Dec; 48(26):8134-47. PubMed ID: 16366595
[TBL] [Abstract][Full Text] [Related]
9. Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.
Perspicace E; Cozzoli L; Gargano EM; Hanke N; Carotti A; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2014 Aug; 83():317-37. PubMed ID: 24974351
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone.
Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
[TBL] [Abstract][Full Text] [Related]
12. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
13. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
Bydal P; Luu-The V; Labrie F; Poirier D
Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
[TBL] [Abstract][Full Text] [Related]
15. Parallel solid-phase synthesis of 3beta-peptido-3alpha-hydroxy-5alpha-androstan-17-one derivatives for inhibition of type 3 17beta-hydroxysteroid dehydrogenase.
Maltais R; Luu-The V; Poirier D
Bioorg Med Chem; 2001 Dec; 9(12):3101-11. PubMed ID: 11711285
[TBL] [Abstract][Full Text] [Related]
16. N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity.
Sam K; Labrie F; Poirier D
Eur J Med Chem; 2000 Feb; 35(2):217-25. PubMed ID: 10758283
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
Le Lain R; Nicholls PJ; Smith HJ; Maharlouie FH
J Enzyme Inhib; 2001 Jan; 16(1):35-45. PubMed ID: 11496833
[TBL] [Abstract][Full Text] [Related]
18. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity.
Qiu W; Campbell RL; Gangloff A; Dupuis P; Boivin RP; Tremblay MR; Poirier D; Lin SX
FASEB J; 2002 Nov; 16(13):1829-31. PubMed ID: 12223444
[TBL] [Abstract][Full Text] [Related]
19. Androsterone derivatives substituted at position 16: chemical synthesis, inhibition of type 3 17beta-hydroxysteroid dehydrogenase, binding affinity for steroid receptors and proliferative/antiproliferative activity on Shionogi (AR+) cells.
Tchédam-Ngatcha B; Luu-The V; Poirier D
J Enzyme Inhib Med Chem; 2002 Jun; 17(3):155-65. PubMed ID: 12443041
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-hydroxyphenyl ketones as potent and specific inhibitors of the type 3 of 17beta-hydroxysteroid dehydrogenase (17beta-HSD3).
Lota RK; Olusanjo MS; Dhanani S; Owen CP; Ahmed S
J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):128-37. PubMed ID: 18620056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
